annb0t
Top 20
MONTREAL, March 28, 2022 /CNW/ -- Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada approval of FLUCELVAX® QUAD (Influenza Vaccine), its cell-based quadrivalent influenza vaccine for an expanded age indication for children as young as six months old.1 With this approval, FLUCELVAX® QUAD, the first cell-based influenza vaccine available in Canada, is now indicated for everyone eligible to receive an influenza vaccine in Canada.2 FLUCELVAXÂ...
>>> Read more: Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months
>>> Read more: Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months
